With regard to the first, c-Met expression has been assessed in various tumor types in the head and neck (82.9% in OSCC (exact location not specified; [33]), 70% in hypopharyngeal cancer [32] and 54.9% in laryngeal carcinoma [35]). Here, MET is linked to hypopharynx cancer.